Andrew J. Cutler | Psychiatrist.com

Original Research

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

Original Research

Extended-Release Carbamazepine Capsules as Monotherapy for Acute Mania in Bipolar Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Original Research

Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder: A Placebo- and Duloxetine-Controlled Study

Original Research

A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram

Original Research

A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder

Original Research

Valbenazine for Tardive Dyskinesia: Results From the KINECT 3 Study

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...

Article

Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories

Reducing functional impairment in patients with major depressive disorder is critical for optimizing treatment outcomes and achieving long-term wellness. In this post hoc analysis, improvement in functional impairment in...

Educational Activity

The Role of Insomnia in Depression and Anxiety: Its Impact on Functioning, Treatment, and Outcomes

Original Research

Response and Remission with DR/ER-MPH

Delayed-release and extended-release methylphenidate (DR/ER-MPH) has shown marked improvement in ADHD symptoms and functional impairment. This post hoc analysis examined response and remission thresholds for DR/ER-MPH in the context...

Original Research

Efficacy and Safety of AR19 in Adults With ADHD

Misuse of stimulant medications prescribed for attention-deficit/hyperactivity disorder (ADHD) can have adverse medical outcomes. This study tested the safety and efficacy of AR19, a manipulation-resistant formulation of amphetamine, in...

Amphetamine Extended-Release Tablets for Adult ADHD

Original Research

Amphetamine Extended-Release Tablets for Adult ADHD

Treating attention-deficit/hyperactivity disorder (ADHD) in adults can improve long-term outcomes, such as reducing suicidal behavior and mortality. This study evaluated the efficacy and safety of amphetamine extended-release tablets in...

Long-Term Safety and Efficacy of Zuranolone in MDD

Original Research

Long-Term Safety and Efficacy of Zuranolone in MDD

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.